Fritextsökning
Artiklar per år
Innehållstyper
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessible to more people. “Our overall ambition is to reduce costs a hundredfold”, says professor Johan Rockberg at KTH Royal Institute of Technology in Stockholm.
-
Roche’s Genentech terminates licencing deal with Norwegian biotech
Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What we see is a significant unmet need, so we are expecting to have quite a good welcoming in the market", says Daniel Lucas, Managing Director Nordic Countries at the American pharmaceutical giant Eli Lilly.
-
New large lab building in Lund inaugurated – here are the companies moving in
Medicon Village has received a new laboratory building. On Friday last week the building was inaugurated with a ribbon-cutting ceremony by Minister for Employment and Integration Mats Persson (L) and construction contractor Mats Paulsson.
-
A new life science cluster formed – “We are very strong in talent”
Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the decision to create a joint profile for the two cities is strongly supported. He mentions that around 50 stakeholders were asked last winter if they were in favour of a joint cluster and that “the answer was a resounding yes”.
-
Mathias Uhlén om kemipriset: ”Största nyttan är för förståelsen av människans biologi”
Årets Nobelpris i kemi gick till forskare som lyckats bygga och förutspå proteiners märkliga struktur. ”All medicinsk forskning har intresse för det här”, säger Mathias Uhlén, hjärnan bakom Human Protein Atlas.
-
This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”
This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understanding the mechanism has changed our view of human biology and evolution, says KI Professor András Simon.
-
Moderna fälls efter 20 000-kronorserbjudande till barn
Moderna kritiseras i Storbritannien för ett felaktigt meddelande där barn erbjöds 1 500 pund, motsvarande över 20 000 kronor, för deltagande i en klinisk studie av bolagets covid-vaccin.
-
Anna Törner: ”Mom, do you think you’ll ever get married again?”
”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence intervals”, Anna Törner writes in a column.
-
Takeover bid is being completed – Japanese company acquires Calliditas
Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided to apply for delisting of the company´s share from Nasdaq Stockholm.
-
Ny kontroversiell studie kopplar fetmaläkemedel till självmordstankar
I både EU och USA har misstänkta kopplingar mellan GLP1-analoger och självmordstankar utretts – och avfärdats. Nu väcks frågan till liv igen av en ny studie.
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other industries for inspiration and knowledge.
-
Life science-staden Göteborg – Vi är ”Lilla Boston”
I Västsverige satsar man på life science inom alltifrån avancerade terapiläkemedel till femtech. Samtidigt blickar aktörerna mot andra branscher för inspiration och kunskap.
-
Carl-Henrik Heldin ny rådgivare åt Rarity Bioscience
Rarity Bioscience får ett tungt tillskott till sitt vetenskapliga råd. Carl-Henrik Heldin, professor vid Uppsala universitet och tidigare styrelseordförande för Nobelstiftelsen, är ny extern rådgivare till bolaget.
-
Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”
The international life science conference Bio Europe is coming to Sweden for the first time in November. The conference, whose program takes inspiration from ABBA songs, turns 30 this year. "There is great interest in Sweden and Swedish solutions globally," says Anna Redwood from Business Sweden.
-
Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”
In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 100 years old, he looks back on an intense life and his upbringing in Stockholm, Sweden, which shaped his desire to help the vulnerable in society.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at Lund University, about research policy, the constant hunt for funding in academia and what constitutes ‘fine research’.
-
Samuel Lagercrantz: “Companies that do this successfully will take the lead”
The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that relieve pain or eliminate painful symptoms, writes Samuel Lagercrantz in an editorial.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
Christina Östberg Lloyd satsar på eget – ”Jag är full av energi”
Efter över tjugo år på olika tjänster inom life science-företag satsar Christina Östberg Lloyd på eget som konsult. ”Detta öppnar upp helt nya perspektiv och möjligheter”, säger hon till Life Science Sweden.
-
Carl Borrebaeck – professor och serieentreprenör med känsla för fart
Prisbelönt cancerforskare, grundare av en hel drös börsbolag, ständigt i den akademiska och kommersiella hetluften under flera decennier. Men Carl Borrebaeck, professor i immunteknologi i Lund, är inte nöjd än. ”Vi har ett nytt, potentiellt superspännande projekt på gång”, säger han.
-
List: The coolest names in biotech
Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuticals, a Swedish, or at least Swedish-British, drug came out on top.
-
Svensk smärtapp får patent i Europa
Lundbaserade Paindrainer har beviljats europeiskt patent för sin AI-baserade plattform för hantering av kronisk smärta.
BREAKING